Recap: Eagle Pharmaceuticals First Quarter Results

Actions of Eagle Pharmaceuticals (NASDAQ: EGRX) was unchanged after the company’s first quarter earnings release.

Quarterly results

Earnings per share fell 71.43% year-over-year to $ 0.24, which missed the estimate of $ 0.65.

Revenue of $ 41,249,000 was down 10.37% from the same period last year, which missed the estimate of $ 45,410,000.

Advice

Eagle Pharmaceuticals has not released a revenue forecast at this time.

The revenue forecast has not been released by the company at this time.

Call details

Date: May 10, 2021

Time: 8:30 a.m.

ET webcast URL: https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&referrer=https%3A%2F%2Finvestor.eagleus.com%2F&eventid=3082041&sessionid=1&key=83C4DAA2D59D2French®ource&sessionid=1&key=83C4DAA2F59D2Frame®58page02

Price action

Company high in 52 weeks was $ 56.16

Company low in 52 weeks was $ 36.48

Price action in the last quarter: + 3.30%

Company Profile

Eagle Pharmaceuticals Inc is a specialty pharmaceutical company. The company develops and markets injectable products in the fields of intensive care, orphan diseases and oncology. Its product portfolio includes four approved products: Argatroban, Ryanodex, Belrapzo and Bendeka. The company currently has several product candidates in advanced stages of development and under review for approval by the Food and Drug Administration.